Cell membrane-camouflaged nanocarriers: A cutting-edge biomimetic technology to develop cancer immunotherapy

被引：1
作者：
Samanta, Rajkumar [1 ,2 ]
Haldar, Niladri [1 ,2 ]
Pamecha, Anchal [3 ]
Gajbhiye, Virendra [1 ,2 ]
机构：
[1] Agharkar Res Inst, Nanobiosci, 411004 AC, Pune 411004, India
[2] Savitribai Phule Pune Univ, Pune 411007, India
[3] Agharkar Res Inst, Nanobiosci Grp, Pl Work, Pune, India
来源：
INTERNATIONAL JOURNAL OF PHARMACEUTICS | 2025年 / 672卷
关键词：
Biomimetic; Cell membrane-coated nanoparticles; Cancer immunity cycle; Cancer Immunotherapy; Immune checkpoint block; Tumor vaccine; COATED NANOPARTICLES; MACROPHAGE-MEMBRANE; MAGNETIC NANOPARTICLES; ANTICANCER VACCINATION; DRUG-DELIVERY; NANOVACCINE; SYSTEM; TOXINS; DOX;
D O I：
10.1016/j.ijpharm.2025.125336
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The development and growth of many diseases are significantly influenced by immune dysregulation. Similarly, uncontrolled tumor growth occurs in cancer because the immune system is unable to identify and eradicate cancer cells. Therefore, to address this issue, cancer immunotherapy plays a crucial role in detecting tumors and inhibiting their growth. This immune-oncotherapy has gained significant interest over the last decade because of its relevant success in biomedical applications. The fundamental goal of immunotherapy in the war against cancer is to develop potent immunotherapies that have minimal side effects and excellent tumor selectivity. To develop these characteristics, nanotechnology offered promising opportunities for cancer immunotherapy. Cell membrane-coated nanoparticles (CMNPs) have recently evolved, which has a tremendous advantage over other nanoparticles (NPs). The CMNPs can be formed by wrapping cell membranes, which can camouflage the specific cell type, allowing these NPs to survive like "self" during blood circulation and escape immune cell capture. These provide NPs with increased biocompatibility, minimal immunogenicity, longer circulation, and targeted tumor therapy. These advantages have made CMNPs a potential delivery vehicle for immunostimulatory drugs, which can induce immunological responses and lead to cancer immunotherapy. Surface modification of CMNPs using cutting-edge genetic engineering techniques revolutionizes cancer immunotherapy to produce new nano- formulations with greater effectiveness. In this review, we briefly discuss the relationship between cancer and the immune system, various techniques of CMNPs synthesis, and the use of naturally occurring and genetically modified CMNPs for cancer immunotherapy.
引用
收藏
页数：27
相关论文
共 135 条
  • [51] Johnson D.T., Et al., Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy, Leukemia, 36, 4, pp. 994-1005, (2022)
  • [52] Kang M., Et al., T-cell-mimicking nanoparticles for cancer immunotherapy, Adv. Mater., 32, 39, pp. 1-10, (2020)
  • [53] Kang M., Kim H.Y., Bhang S.H., T-cell membrane coating for improving polymeric nanoparticle-based cancer therapy, J. Ind. Eng. Chem., 119, pp. 252-260, (2023)
  • [54] Korake S., Shaikh A., Salve R., Gajbhiye K.R., Gajbhiye V., Pawar A., Biodegradable dendritic Boltorn<sup>TM</sup> nanoconstructs: A promising avenue for cancer theranostics, Int. J. Pharm., 594, February, pp. 1-7, (2021)
  • [55] Krishnan N., Et al., A modular approach to enhancing cell membrane-coated nanoparticle functionality using genetic engineering, Nat. Nanotechnol., 19, 3, pp. 345-353, (2024)
  • [56] Krishnan N., Fang R.H., Zhang L., Cell membrane‐coated nanoparticles for the treatment of cancer, Clin. Transl. Med., 13, 6, pp. 11-13, (2023)
  • [57] Kumar P., Salve R., Paknikar K.M., Gajbhiye V., Nucleolin aptamer conjugated MSNPs-PLR-PEG multifunctional nanoconstructs for targeted co-delivery of anticancer drug and siRNA to counter drug resistance in TNBC, Int. J. Biol. Macromol., 229, pp. 600-614, (2023)
  • [58] Kumar P., Paknikar K.M., Gajbhiye V., A robust pH-sensitive unimolecular dendritic nanocarrier that enables targeted anti-cancer drug delivery via GLUT transporters, Colloids Surfaces B Biointerfaces, 171, July, pp. 437-444, (2018)
  • [59] Le Q.V., Lee J., Lee H., Shim G., Oh Y.K., Cell membrane-derived vesicles for delivery of therapeutic agents, Acta Pharm. Sin. B, 11, 8, pp. 2096-2113, (2021)
  • [60] Li M., Et al., Red blood cell membrane-coated upconversion nanoparticles for pretargeted multimodality imaging of triple-negative breast cancer, Biomater. Sci., 8, 7, pp. 1802-1814, (2020)
12345678910